OmniAb (OABI)
Provides antibody-discovery technologies that feed partner drug programs and royalty economics.
Something off on this page? Send us feedback.
Sells access to antibody-discovery technologies, research services, screening tools, and downstream royalty rights tied to partner programs. The business is concentrated in a single discovery-technology segment and depends on partners advancing OmniAb-derived antibodies into development and commercialization.
Provides partner access to antibody-discovery technologies rather than selling owned drugs. The suite spans transgenic animal platforms such as OmniRat, OmniMouse, OmniChicken, OmnidAb, OmniUltra, and OmniTaur, plus xPloration single B-cell screening, computational discovery tools, and ion-channel expertise.
Revenue comes from technology access, research services, xPloration activity, milestones, and potential royalties when partner programs progress. The business is reported as a single discovery research technology segment and competes in a global market for therapeutic-antibody discovery tools.
Future economics depend on partners choosing the platform, moving OmniAb-derived antibodies through development, and commercializing approved products. Intellectual-property barriers, in-house pharma discovery teams, and specialized discovery-tool competitors shape the market.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $52.0M · Total debt $18.9M · Total assets $290.3M · Shareholders' equity $260.3M
- Revenue
- $13.4M
- Operating income
- −$6.6M
- Net income
- −$5.9M
No dividends on record.
| Institutions | 41.10% | 59.76M shares | |
|---|---|---|---|
| 135 holders · as of Jun 30, 2026 | |||
| Insiders | 5.85% | 8.50M shares | |
| 9 holders · as of Jun 18, 2026 | |||
| Other | 53.05% | 77.13M shares | |
| remainder | |||
145.39M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Whitefort Capital Management, LPInstitution | 7.05% | 10.25M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.12% | 8.90M | as of Jun 30, 2026 |
Ash X LPInstitution | 5.20% | 7.56M | filed Feb 10, 2026 |
Nomura Holdings IncInstitution | 3.46% | 5.03M | as of Jun 30, 2026 |
Matthew W. FoehrInsiderdirector, officer: President and CEO | 3.04% | 4.42M | filed Apr 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 7, 2026 | Charles S. Berkman | officer: Chief Legal Officer | −7,157 | $1.49 |
| Apr 7, 2026 | Kurt A. Gustafson | officer: Executive VP, Finance and CFO | −6,913 | $1.49 |
| Apr 7, 2026 | Matthew W. Foehr | director, officer: President and CEO | −19,244 | $1.49 |
| Feb 18, 2026 | Matthew W. Foehr | director, officer: President and CEO | −30,843 | $1.71 |
| Feb 18, 2026 | Kurt A. Gustafson | officer: Executive VP, Finance and CFO | −9,301 | $1.71 |
- AbCellera Biologics
Closest antibody-discovery platform peer with single-cell depth
- Twist Bioscience
Synthetic-library and in vivo antibody discovery alternative
- Bruker
Single-cell screening instrument peer for antibody campaigns
- Charles River Laboratories
CRO peer across antibody discovery and ion-channel assays
- Regeneron
VelocImmune transgenic-mouse and internal discovery competitor
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| OmniAb | $4.73 | +3.17% | $664.0M | — | — | 17.3 | +244.2% |
| AbCellera Biologics | $12.92 | +2.06% | $3.87B | — | — | 58.4 | −76.3% |
| Twist Bioscience | $168.03 | +1.33% | $10.33B | — | — | 23.9 | +23.3% |
| Bruker | $61.71 | +0.20% | $9.37B | — | 27.2 | 2.7 | +5.2% |
| Charles River Laboratories | $287.12 | +2.91% | $13.44B | — | 23.3 | 3.4 | −2.7% |
| Regeneron | $805.02 | +0.86% | $82.23B | 19.7 | 13.3 | 5.3 | +16.7% |
| Median | 19.7 | 23.3 | 5.3 | +5.2% |